Aspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 30 Oct, 02:38 UTC

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition.